About the Phase 1 Study of YL-13027
Trial: YL-13027 in Patients With Advanced Solid Tumors
Recruitment Status: Recruiting
Estimated Enrollment: 54 Participants
Summary: This is a dose escalation, 3 + 3 design study, to evaluate the safety and tolerability, and to determine the RP2D of YL-13027 when administered b.i.d. in patients with advanced solid tumors. Up to 4 cohorts of 3-6 patients each will be treated in part 1 of the study. One cycle is 28 days. Part 2 is a dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of YL-13027 at the RP2D.
Intervention Model Described: Single Group Assignment
ClinicalTrials.gov Identifier: NCT05228600